Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of down syndrome

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  García Cerro, Susana ^a   Martínez, Paula ^a   Vidal, Verónica ^a   Corrales, Andrea ^a   Flórez, Jesús ^a   Vidal, Rebeca ^a,b,c   Rueda, Noemí ^a   Arbonés, María L ^d   Martínez Cué, Carmen ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b University of Cantabria   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; PROTEIN DYRK1A; UNCLASSIFIED DRUG; DYRK KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE;

ADULT; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CELL; BRAIN ELECTROPHYSIOLOGY; CELL DIFFERENTIATION; CELL PROLIFERATION; COGNITIVE DEFECT; CONTROLLED STUDY; DENTATE GYRUS; DOWN SYNDROME; DYRK1A GENE; EXPERIMENTAL COGNITIVE TEST; FEAR CONDITIONING TEST; FEMALE; GABAERGIC SYSTEM; GENE; GENE DOSAGE; GENE OVEREXPRESSION; HIPPOCAMPUS; LONG TERM POTENTIATION; MORPHOLOGICAL TRAIT; MORRIS WATER MAZE TEST; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PHENOTYPE; PROGENY; TASK PERFORMANCE; ANIMAL; COGNITION; DISEASE MODEL; GENETICS; MALE; MEMORY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; COGNITION; DISEASE MODELS, ANIMAL; DOWN SYNDROME; FEMALE; LONG-TERM POTENTIATION; MALE; MEMORY; MICE; MICE, TRANSGENIC; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES;

EID: 84906962936     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106572     Document Type: Article

References (79)

1. Bartesaghi R, Guidi S, Ciani E (2011) Is it possible to improve neurodevelopmental abnormalities in Down syndrome? Rev Neurosci 22: 419-455.
2. Rueda N, Flórez J, Martínez-Cué C (2012) Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities. NeuralPlasticity 584071. doi:10.1155/2012/584071.
3. Contestabile A, Greco B, Ghezzi D, Tucci V, Benfenati F, et al. (2013) Lithium rescues synaptic plasticity and memory in Down syndrome mice. J Clin Invest 123: 348-361.
4. Becker W, Sippl W (2011) Activation, regulation, and inhibition of DYRK1A. FEBS J 278: 246-256.
5. Guedj F, Lopes Pereira P, Najas S, Barallobre M-J, Chabert C, et al. (2012) DYRK1A: A master regulatory protein controlling brain growth. Neurobiol Dis 46: 190-203.
6. Tejedor FJ, Hämmerle B (2011) MNB/DYRK1A as a multiple regulator of neuronal development. FEBS J 278: 223-235.
7. Altafaj X, Martín ED, Ortiz-Abalia J, Valderrama A, Lao-Peregrn C, et al. (2013) Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis 52: 117-127.
8. Smith DJ, Stevens ME, Sudanagunta SP, Bronson RT, Makhinson M, et al. (1997) Functional screining of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat Genet 16: 28-36.
9. Altafaj X, Dierssen M, Baamonde C, Martí E, Visa J, et al. (2001) Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum Mol Genet 10: 1915-1923.
10. Ahn KJ, Jeong HK, Choi HS, Ryoo S-R, Kim YJ, et al. (2006) DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects. Neurobiol Dis 22: 463-472.
11. De la Torre R, De Sola S, Pons M, Duchon A, de Lagran MM, et al. (2014) Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and humans. Mol Nutr Food Res 58: 278-288.
12. Branchi I, Bichler Z, Minghetti L, Delabar JM, Malchiodi-Albedi F (2004) Transgenic mouse in vivo library of human Down syndrome critical region 1: association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration. J Neuropathol Exp Neurol 63: 429-440.
13. Sebrié C, Chabert C, Ledru A, Guedj F, Po C, et al. (2008) Increased dosage of DYRK1A and brain volumentric alterations in a YAC model of partial trisomy. Anat Records 291: 254-262.
14. Ortiz-Abalia J, Sahún I, Altafaj X, Andreu N, Estivill X, et al. (2008) Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome. Am J Hum Genet 83: 479-488.
15. McKay S M, Angulo-Barroso RM (2006) Longitudinal assessment of leg motor activity and sleep patterns in infants with and without Down syndrome. Infant Behav Dev 29: 153-168.
16. Nishizawa Y, Fujita T, Matsuoka K, Nakagawa H (2006) Contact pressure distribution features in Down syndrome infants in supine and prone positions, analyzed by photoelastic methods. Pediatr Int 48: 484-488.
17. Pereira K, Basso RP, Lindquist AR, da Silva AG, Tudella E (2013) Infants with Down syndrome: percentage and age for acquisition of gross motor skills. Res Dev Disabil 34: 894-901.
18. Escorihuela R M, Fernández-Teruel A, Vallina IF, Baamonde C, Lumbreras MA, et al. (1995) A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci Lett 199: 143-146.
19. Baxter LL, Moran TH, Richtsmeier JT, Troncoso J, Reeves RH (2000) Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Hum Mol Genet. 9: 195-202.
20. Martínez-Cué C, Martínez P, Rueda N, Vidal R, Garca S, et al. (2013) Reducing GABAA a5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of Down syndrome. J Neurosci 33: 3953-3966.
21. Crnic LS, Pennington BF (2000) Down sndrome: neurophychology and animals models. Progress in Infancy Research 1: 69-111.
22. Martínez-Cué C, Rueda N, Garca E, Flórez J (2006) Anxiety and panic responses to a predator in male and female Ts65Dn mice, a model for Down syndrome. Genes Brain Behav 5: 413-422.
23. Martínez-Cué C, Delatour B, Potier MC (2014) Treating enhanced GABAergic inhibition in Down syndrome: Use of GABA alfa5-selective inverse agonists. Neurosci Biobehav Rev, in press. Doi:10.1016/jneurobiorev.2013.12.008.
24. Park J, Oh Y, Yoo L, Jung MS, Song WJ, et al. (2010) Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells. J Biol Chem 285: 31895-31906.
25. Yabut O, Domagauer J, D'Arcangelo G (2010) Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells. J Neurosci 30: 4004-4014.
26. Shors TJ, Townsend DA, Zhao M, Kozorovitskiy Y, Gould E (2002) Neurogenesis may relate to some but not all types of hippocampal-dependent learning. Hippocampus 12: 578-84.
27. Shors TJ, Miesegaes G, Beylin A, Zhao M, Rydel T, et al. (2001) Neurogenesis in the adult is involved in the formation of trace memories. Nature 410: 372-6.
28. Imayoshi I, Sakamoto M, Ohtsuka T, Takao K, Miyakawa T, et al. (2008) Roles of continuous neurogenesis in the structural and functional integrity of the adult forebrain. Nat Neurosci 11: 1153-1161.
29. Thomazeau A, Lassalle O, Iafrati J, Souchet B, Guedj F, et al. (2014) Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene dyrk1a. J Neurosci 22: 1138-1147.
30. Tozuka Y, Fukuda S, Namba T, Seki T, Hisatsune T (2005) GABAergic excitation promotes neuronal differentiation in adult hippocampal progenitor cells. Neuron 47: 803-815.
31. Ge S, Goh EL, Sailor KA, Kitabatake Y, Ming GL, et al. (2006) GABA regulates synaptic integration of newly generated neurons in the adult brain. Nature 439: 589-593.
32. Earnheart JC, Schweizer C, Crestani F, Iwasato T, Itohara S, et al. (2007) GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states. J Neurosci 27: 3845-3854.
33. Bortone D, Polleux F (2009) KCC2 expression promotes the termination of cortical interneuron migration in a voltage-sensitive calcium-dependent manner. Neuron 62: 53-71.
34. Fotaki V, Dierssen M, Alcántara S, Martínez S, Martí E, et al. (2002) Dyrk1A haploinsufficiency affects viability and casues developmental delay and abnormal brain morphology in mice. Mol Cell Biol 22: 6636-6647.
35. Liu DP, Schmidt C, Billings T, Davisson MT (2003) A quantitative PCR genotyping assay for the Ts65Dn mouse model of Down syndrome. Biotechniques 35: 1170-1174.
36. Bowes C, Li T, Frankel WN, Danciger M, Coffin JM, et al. (1993) Localization of a retroviral element within the rd gene coding for the beta subunit of cGMP phosphodiesterase. Proc Natl Acad Sci USA 90: 2955-2959.
37. Rueda N, Flórez J, Martínez-Cué C (2013) Apoptosis in Down's syndrome: lessons from studies of human and mouse models. Apoptosis 18: 121-134.
38. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
39. Steele RJ, Morris RG (1999) Delay-dependent impairment of a matching-toplace task with chronic intrahippocampal infusion of the NMDA-antagonist DAP5. Hippocampus 9: 118-136.
40. Chen G, Chen KS, Knox J, Inglis J, Bernard A, et al. (2000) A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408: 975-979.
41. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, et al. (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18: 602-617.
42. Saab BJ, Saab AMP, Roder JC (2011) Statistical and theoretical considerations for the platform re-location water maze. J Neurosci Methods 198: 44-52.
43. Olton DS, Papas BC (1979) Spatial memory and hippocampal function. Neuropsychologia 17: 669-682.
44. Salehi A, Faizi M, Colas D, Valletta J, Laguna J, et al. (2009) Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci Trans Med 18: 7ra17.
45. LLorens-Martín MV, Torres-Alemán I, Trejo JL (2006) Pronounced individual variation in the response to the stimulatory action of exercise on immature hippocampal neurons. Hippocampus 16: 480-490.
46. Costa AC, Walsh K, Davisson MT (1999) Motor dysfunction in a mouse model for Down syndrome. Physiol Behav 68: 211-220.
47. Souchet B, Guedj F, Sahún I, Duchon A, Daubigney F, et al. (2014) Excitation/inhibition balance and learning are modified by Dyrk1a gene dosage. Neurobiol Dis 69: 65-75.
48. Sturgeon X, Gardiner KJ (2011) Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm Genome 22: 261-271.
49. Duchon A, Raveau M, Chevalier C, Nalesso V, Sharp A, et al. (2011) Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modelling Down syndrome. Mamm Genome 22: 674-678.
50. Campeau S, Davis M (1995) Involvement of subcortical and cortical afferents to the lateral nucleus of the amygdala in fear conditioning measured with fearpotentiated startle in rats trained concurrently with auditory and visual conditioned stimuli: J Neurosci 15: 2312-2327.
51. Goosens KA, Maren S (2001) Contextual and auditory fear conditioning are mediated by the lateral, basal, and central amygdaloid nuclei in rats. Learn Mem 8: 148-155.
52. Kholodar-Smith D B, Allen TA, Brown TH (2008) Fear conditioning to discontinuous auditory cues requires perirhinal cortical function. Behav Neurosci 122: 1178-85.
53. Anagnostaras SG, Gale GD, Fanselow MS (2001) Hippocampus and contextual fear conditioning: recent controversies and advances. Hippocampus 11: 8-17.
54. Biedenkapp JC, Rudy JW (2009) Hippocampal and extrahippocampal systems compete for control of contextual fear. role of ventral subiculum and amygdala. Learn Mem 16: 38-45.
55. Sacchetti B, Baldi E, Lorenzini CA, Bucherelli C (2002) Cerebellar role in fearconditioning consolidation. Proc Natl Acad Sci U S A 99 8406-8411.
56. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11: 47-60.
57. Goldman-Rakic PS (1999) The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry 46: 650-661.
58. Wang GW, Ci JX (2006) Disconnection of the hippocampus-prefrontal cortical circuits impairs spatial working memory performance in rats. Behav Brain Res 175: 329-336.
59. Seamans JK, Floresco SB, Phillips AG (1995) Functional differences between the prelimbic and anterior cingulated regions of the rat prefrontal cortex. Behav Neurosci 109: 1063-1073.
60. Goto Y, Yang CR, Otani S (2010) Functional and dysfunctional plasticity in the prefrontal cortex: roles in psychiatric disorders. Biol Psychiatry 67: 199-207.
61. Guedj F, Sebrie C, Rivals I, Ledru A, Paly A, et al. (2009) Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PlosOne 4: 1-8.
62. Xie W, Ramakrishna N, Wieraszko A, Hwang YW (2008) Promotion of neuronal plasticity by (-)-epigallocatechin-3-galate. Neurochem Res 33: 776-783.
63. Kleschevnikov AM, Belichenko PV, Villar AJ, Epstein CJ, Malenka RC, et al. (2004) Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J Neurosci 24: 8153-8160.
64. Fernandez F, Morishita W, Zuniga E, Nguyen J, Blank M, et al. (2007) Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci 10: 411-413.
65. Belichenko PV, Kleschevnikov AM, Masliah E, Wu C, Takimoto-Kimura R, et al. (2009) Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome. J Comp Neurol 512: 453-466.
66. Braudeau J, Delatour B, Duchon A, Pereira PL, Dauphinot L, et al. (2011) Specific targeting of the GABA-A receptor alpha5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. J Psychopharmacol 25: 1030-1042.
67. Colas D, Chuluun B, Warrier D, Blank M, Wetmore DZ, et al. (2013) Shortterm treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down's syndrome. Br J Pharmacol 169: 963-973.
68. Pérez-Cremades D, Hernández S, Blasco-Ibán?ez JM, Crespo C, Nacher J, et al. (2010) Alteration of inhibitory circuits in the somatosensory cortex of Ts65Dn mice, a model for Down's syndrome. J Neural Transm 117: 445-455.
69. Chakrabarti L, Best TK, Cramer NP, Carney RS, Isaac JT, et al. (2010) Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Nat Neurosci 13: 927-934.
70. Bianchi P, Ciani E, Guidi S, Trazzi S, Felice D, et al. (2010) Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J Neurosci 30: 8769-8779.
71. Hiaoui Y, Grad I, Letourneau A, Sailani MR, Dahoun S, et al. (2014) Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy. EMBO Mol Med 6: 259-277.
72. Garthe A, Kempermann G (2013) And old test for new neurons: refining the Morris water maze to study the functional relevance of adult hippocampal neurogenesis. Front Neurosci 7,63.
73. Pérez-Domper P, Gradari S, Trejo JL (2013) The growth factors cascade and the dendrito2/synapto-genesis versus cell survival in adult hippocampal neurogenesis: the chicken or the egg. Ageing Res Rev 12: 777-785.
74. Schebesta M, Serluca FC (2009) Olig1 expression identifies developing oligodendrocytes in zebrafish and requires hedgehog and notch signaling. Dev Dynamics 238: 887-898.
75. Tiso N, Filippi A, Benato F, Negrisolo E, Modena N, et al. (2009) Differential expression and regulation of Olig genes in zebrafish. J Comp Neurol 515: 378-396.
76. Guo X, Williams JG, Schug TT, Li X (2010) DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1. J Biol Chem 285: 13223-13232.
77. Laguna A, Barallobre MJ, Marchena MÁ, Mateus C, Ram
78. Laguna A, Aranda S, Barallobre MJ, Barhoum R, Fernández E, et al. (2008) The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development. Dev Cell 15: 841-853.
79. Rueda N, Flórez J, Martínez-Cué C (2011) The Ts65Dn mouse model of Down syndrome shows reduced expression of the Bcl-X(L) antiapoptotic protein in the hippocampus not accompanied by changes in molecular or cellular markers of cell death. Int J Dev Neurosci 29: 711-716.